Douglas Yee is an Oncology physician affiliated with University of Minnesota. OpenAlex indexes 581 publications with 26,060 citations (h-index 83); ClinicalTrials.gov lists 4 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Masonic Cancer Center, First Floor, Suite M100
424 Harvard Street SE
Minneapolis, MN 55455
Telephone
612-625-5411Registry record last updated 15 Feb 2013.
Clinical trials
- Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery
Sponsor: Masonic Cancer Center, University of Minnesota
- Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca
Sponsor: Masonic Cancer Center, University of Minnesota
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Teleflex LLCProgram year20231 payment
- Boehringer Ingelheim International GmbHProgram year20212 payments
- Gilead Sciences, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Estrogen Agonist/Antagonist60.5%Tamoxifen Citrate100%Part D<11 patientsAromatase Inhibitor39.5%Anastrozole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
8 NIH research awards on record, funded 1999–2026 per NIH RePORTER. The latest:
- Progesterone Receptor (PR) Signaling Cross Talk Drives ER+ Breast Cancer
University of Minnesota
FY2026$652,355R01CA229697
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Blazar, MD
University of Minnesota
Jay Cohn, MD
University of Minnesota
Julia Steinberger, MD
University of Minnesota
Charles Herzog, MD
University of Minnesota
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”